Key information

🔎 Fund Overview

Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The Company is focused on therapeutics targeting untreatable eye diseases involving retinal degeneration, such as atrophic age-related macular degeneration (dry AMD) and autosomal recessive Stargardt disease (STGD1), both of which progressively lead to permanent blindness, and metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout. The Company is developing LBS-008 as an oral daily treatment for STGD1 and dry AMD. LBS-008 is a therapy targeting dry AMD and STGD1, which are untreatable conditions that cause progressive vision loss in affected individuals. LBS-008 is an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A (retinol) to the eye. The Company's LBS-009 is an anti-Retinol binding protein 4 (RBP4) oral therapy targeting liver disease, including NAFLD, NASH, and T2D.